-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say. Read more…
Recent articles
Get the latest Long COVID news and commentary
Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
Check out our weekly podcast, Still Here
Spotify
Apple Podcasts
PocketCasts
iHeartRadio
RSS
Policy & Advocacy
-
Despite the ongoing pandemic, some companies are banning employees from masking
-
Violet Affleck advocates for children with Long COVID, masks, and clean indoor air at United Nations event
-
Letter to the editors: Concerns about California’s right-to-mask bill
-
Kennedy’s HHS commits to Long COVID, but without clear funding
-
How do you get people to care about COVID-19? Here’s what I’ve learned as an organizer.
-
Left without care: Many Long COVID clinics are closing down in the U.K.
Science
Covid-19
Health
-
Telehealth is vital for people with Long COVID. Don’t let it disappear.
-
Despite Long COVID’s ongoing impact, research in Colombia is limited
-
“Medically neglected” and “structurally erased”: International network appeals for ME advocate Nevra Elis
-
The future of Medicaid is “really scary” for people with Long COVID
-
International Long COVID conference spotlights biomarker and mechanism research
-
Less than 20% of Long COVID trials involving exercise even mention post-exertional malaise
-
Between two crises: Living with Post-COVID Vaccine Syndrome in a Long COVID world
-
Video essay: How does Long COVID affect queer and trans communities?
-
Universities get an F on Long COVID. Here’s how they can support their students and reduce COVID-19 cases.
-
Even stones break in this heat: Experiencing Long COVID in Indonesia